HUM Stock Price Today (October 2026) — Humana Inc. Analysis & Key Metrics 2026-10-07
Humana Inc. (HUM) is trading at $396.51, down 1.92% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $423.74 (6.9% upside).
- Volatility is moderate (28.60% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (26.20% YoY) alongside competitive pressures in the Healthcare Plans space.
HUM Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Humana Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $38.49B
P/E Ratio
Forward P/E: 23.13
Revenue Growth
Year over Year
Analyst Target
+6.9% upside potential
Key Investor Questions About HUM
What investors need to know before buying
Based on current market data, HUM presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 54.15)
- Fundamentals say: Looking solid (debt and growth supportive)
HUM's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HUM investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $14.74B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, HUM stock traded between $163.11 and $428.88 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 28.60% annualized volatility and β=0.52, the stock exhibits low sensitivity to market moves—making HUM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Humana (HUM) Stock Is Up Today
Shares of health insurance company Humana (NYSE:HUM) jumped 8% in the afternoon session after Barclays upgraded the stock from Equalweight to Overweight.
Humana Stock Jumps. Why It Could Be a Big Winner in Next Medicare Star Ratings.
Barclays upgraded Humana stock to Overweight from Neutral and raised its price target to $515 from $407.
Humana surges: Barclays bets big on Medicare star ratings rebound
Investing.com -- Humana Inc. (NYSE:HUM) shares rose 6% Friday after Barclays upgraded the health insurer to overweight from equal-weight ahead of the upcoming Medicare Star ratings release.
Humana Jumps 7% on Barclays Upgrade and $515 Target; UnitedHealth Nudges Higher
Barclays just broke its silence on Humana with a conviction call that sent shares surging well past anything the broader health care sector is doing today, raising the question of whether this upgrade signals the start of something bigger or a rally built on a single opinion.
Humana Is Dropping Plans Covering 600,000 Members and Hopes 240,000 Choose Humana Again. The Replacement Is Not the Same Plan
Humana is exiting plans and counting on hundreds of thousands of affected members to land back inside the company. Before you accept what arrives in that envelope this fall, there are four terms in the replacement plan that can quietly cost you thousands.
Losing Your Medicare Plan? There’s a Silver Lining.
Americans on Medicare Advantage plans may soon get a breakup letter in the mail: Your insurer is canceling your plan. Humana and other Advantage insurers are sending letters this fall to plan members about 2027 coverage. As insurers look to cut costs, some are discontinuing their Advantage plans.
Humana (HUM) Stock Could Trade At A Discount Following Its 54% Rebound
Humana has staged a sharp rebound in 2024, and with the stock closing at US$407.02, the big question is whether that move still lines up with what the business earns. With the share price up 53.9% year to date, a lot of future expectations are already riding on Humana's earnings power. New research on integrated specialty pharmacy and the push toward lower drug costs may support more stable margins and cash flows, provided Humana can keep members engaged in these models. The analysts...
CLOV Stock Hits Over 2-Month High As Humana Deal Buzz Builds Ahead Of Investor Conferences
Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.
CVS Stock Returned $24B In Cash: Why Did It Still Lag The Market?
The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here’s the accounting of what that trade-off actually delivered.
Should You Buy UNH Stock Because Its Cash Runs Ahead Of Its Profit?
UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.
Explore More Analysis for HUM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 6, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Humana Inc.
Humana Inc. (HUM) is currently trading at $396.51. The RSI (14-day) is at 54.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $423.74 implies 6.9% upside from current levels. Volatility is moderate at 28.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Humana Inc. (HUM): The trailing P/E ratio is 38.76, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 23.13, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.22, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 2.54. Price-to-Sales is 0.34. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering HUM, the consensus price target is $423.74. This represents a 6.9% upside from the current price of $396.51. The range spans from a low target of $280.00 to a high target of $515.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Humana Inc. (HUM) pays a dividend with a current yield of approximately 0.89%. The annualized dividend rate is $3.54 per share. The payout ratio is 33.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Oct 30, 2026.
Key risks for Humana Inc. (HUM) investors include: 1. Moderate volatility (28.6% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Humana Inc.'s (HUM) current debt and financial health profile: Total debt stands at $14.74B. The debt-to-equity ratio is 0.76x, which is moderate and generally manageable for most companies. The current ratio is 1.74, indicating strong short-term liquidity. The quick ratio is 1.29. The company holds $23.87B in cash and equivalents. Free cash flow is positive at $1.94B, providing a cushion for debt servicing and shareholder returns.